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Abstract
Background: Macrophage-derived lymphatic endothelial cell progenitors (M-LECPs) contribute to new lymphatic vessel
formation, but the mechanisms regulating their differentiation, recruitment, and function are poorly understood. Detailed
characterization of M-LECPs is limited by low frequency in vivo and lack of model systems allowing in-depth molecular
analyses in vitro. Our goal was to establish a cell culture model to characterize inflammation-induced macrophage-to-LECP
differentiation under controlled conditions.
Methodology/Principal Findings: Time-course analysis of diaphragms from lipopolysaccharide (LPS)-treated mice revealed
rapid mobilization of bone marrow-derived and peritoneal macrophages to the proximity of lymphatic vessels followed by
widespread (,50%) incorporation of M-LECPs into the inflamed lymphatic vasculature. A differentiation shift toward the
lymphatic phenotype was found in three LPS-induced subsets of activated macrophages that were positive for VEGFR-3 and
many other lymphatic-specific markers. VEGFR-3 was strongly elevated in the early stage of macrophage transition to LECPs
but undetectable in M-LECPs prior to vascular integration. Similar transient pattern of VEGFR-3 expression was found in
RAW264.7 macrophages activated by LPS in vitro. Activated RAW264.7 cells co-expressed VEGF-C that induced an autocrine
signaling loop as indicated by VEGFR-3 phosphorylation inhibited by a soluble receptor. LPS-activated RAW264.7
macrophages also showed a 68% overlap with endogenous CD11b
+/VEGFR-3
+ LECPs in the expression of lymphatic-specific
genes. Moreover, when injected into LPS- but not saline-treated mice, GFP-tagged RAW264.7 cells massively infiltrated the
inflamed diaphragm followed by integration into 18% of lymphatic vessels.
Conclusions/Significance: We present a new model for macrophage-LECP differentiation based on LPS activation of
cultured RAW264.7 cells. This system designated here as the ‘‘RAW model’’ mimics fundamental features of endogenous M-
LECPs. Unlike native LECPs, this model is unrestricted by cell numbers, heterogeneity of population, and ability to change
genetic composition for experimental purposes. As such, this model can provide a valuable tool for understanding the LECP
and lymphatic biology.
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Introduction
The lymphatic system has important functions in human
physiology and pathology including regulation of interstitial fluid
balance [1,2], lipid absorption [3], immunity [4], inflammation [5]
and metastatic spread [6,7]. During embryogenesis, the formation
of new lymphatic vessels (i.e., lymphangiogenesis) is a highly active
process. In contrast, in adults, this process is largely restricted to
sites of cancer [6,7], chronic inflammation [8–12], and tissue
remodeling [13,14]. The key regulatory protein that induces
lymphangiogenesis is the tyrosine kinase receptor VEGFR-3
[15,16]. This protein is highly expressed in lymphatic endothelial
cells (LECs) [17,18] and upregulated in response to inflammation
[17]. The central role of VEGFR-3 in lymphangiogenesis is shown
by a significant reduction in lymphatic vessel density following
VEGFR-3 blockade during chronic inflammation [8], wound
healing [19], and malignancy [20]. In line with this evidence, we
recently showed in the mouse peritonitis model of inflammatory
lymphangiogenesis that activated NF-kB upregulates VEGFR-3
on inflamed lymphatic vessels [17]. This event is crucial for
lymphangiogenesis because it amplifies the responsiveness of pre-
existing lymphatic vessels to VEGFR-3 ligands, VEGF-C and
VEGF-D [16,21] that can be produced by many cell sources
including stromal [22], epithelial [23], malignant [6] and immune
cells [8,24,25].
Postnatal lymphangiogenesis has long been thought to occur
exclusively through sprouting of pre-existing lymphatic vessels, a
process that involves proliferation and migration of fully
differentiated LECs [26]. Recent reports, however, have shown
that lymphangiogenesis can also be regulated by bone marrow
(BM)-derived lymphatic endothelial cell progenitors (LECPs) that
comprise a small fraction of LECs in newly formed lymphatic
vessels [27–32]. The role of LECPs is based on studies
demonstrating that LECPs are recruited to inflamed sites [28–
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majority of studies have suggested that LECPs are derived from
myeloid cells of the monocyte/macrophage lineage [29–31,33],
although other sources may include embryonic stem cells (ESC)
[34] and those from mesenchymal (MSC) [35] and hematopoietic
(HSC) [27] origins. Macrophage-derived LECPs (M-LECPs) have
been identified by lymphatic vascular integration of cells with dual
positivity for myeloid (e.g., CD11b) and lymphatic-specific
markers (e.g., LYVE-1). This was first demonstrated in biopsies
of gender-mismatched human renal transplants that revealed
integration of donor-derived macrophage LECPs into recipient
lymphatic vessels [29]. Similar findings have also been reported in
animal models of corneal inflammation [30,33], wound healing
[31], cancer [28,30,31], and in studies using adoptive BM-transfer
from GFP-transgenic mice to non-transgenic recipients [28,31].
Importantly, GFP-labeled LECPs not only quickly integrated into
the nascent vessels during the first week post-transfer [31], but also
remained in the lymphatic vasculature for at least six months [28].
This suggested that adult LECPs might be involved in both
induction of lymphangiogenesis and the maintenance of the newly-
formed vessels.
Despite the growing body of evidence indicating the important
role of LECPs in lymphangiogenesis, little is known about the
LECP phenotype, mechanisms of recruitment, differentiation into
mature LECs, and roles in vascular remodeling. The obstacles to
gaining this information are mainly due to three reasons: 1) low (2–
5%) frequency of LECP incorporation into vessels [27–29], 2)
limits of the methods for detection of LECPs, and 3) difficulties
monitoring their fate in vivo due to loss of myeloid markers after
integration into lymphatic vasculature. These difficulties are
further compounded by macrophage secretion of pro-lymphan-
giogenic factors (i.e., VEGF-C, -D and -A) that stimulate
lymphangiogenesis directly, without integration of macrophage-
derived progenitors into vasculature. Consequently, while a
macrophage depletion method can be successfully used to
demonstrate dependence of lymphangiogenesis on M-LECPs
[28,33], this approach does not discern between the paracrine
effects of macrophage-derived lymphangiogenic factors and the
autonomous roles of M-LECPs.
These challenges prompted us to search for a cell culture model
that can be manipulated under controlled conditions to allow
delineation of the molecular and cellular events underlying the
lymphangiogenic function of adult M-LECPs. This approach has
been successfully used to model blood vascular endothelial cell
progenitors (BVECPs) [36] suggesting that a similar strategy can be
applied to modeling macrophage-to-LECP transdifferentiation.
Since M-LECPs are known to partake in inflammatory lymphan-
giogenesis [29–31,33], we hypothesized that the lymphatic
phenotype can be induced in cultured macrophages by an
inflammatory stimulator suchas LPS. We found that LPS treatment
of RAW264.7 macrophages, a cell line that normally lacks LEC
markers, induces coincident de novo expression of VEGFR-3 and
VEGF-C leading to establishment of a novel autocrine loop.
ActivationofVEGFR-3pathwaypromptedmacrophagestoexpress
a variety of lymphatic-specific genes, including LYVE-1, c-Maf,
integrin alpha9, Notch1 and podoplanin. Moreover, upon injection
into LPS- but not saline-treated mice, GFP-tagged RAW264.7
macrophages (RAW-GFP) formed large clusters that first firmly
adhered to lymphatic endothelium followed by integration into
approximately one-fifth of the inflamed vessels. This behavior
recapitulated that of endogenous M-LECPs which were found to be
firstmassivelyrecruitedtodiaphragmsinLPS-treatedmicefollowed
by quick incorporation into ,50% of the inflamed lymphatic
vasculature. RT-qPCR analysis showed that LPS-activated
RAW264.7 cells in vitro and endogenous VEGFR-3
+ M-LECPs
isolated from LPS-treated mice have a 68% overlap in expression of
lymphatic-specific genes. Collectively, these findings suggest that
LPS-treated macrophage RAW264.7 line recapitulates both gene
expression profile and the biological behavior of M-LECPs
recruited to inflammatory lymphangiogenic sites in vivo. We,
therefore, believe that this novel model of macrophage-to-LECP
differentiation can provide a unique means for delineating
molecular, cellular, and systemic mechanisms of inflammatory
lymphangiogenesis both in vitro and in vivo.
Results
LPS induces VEGFR-3 expression in several subsets of
activated macrophages in vivo
Macrophages expressing LEC-markers that may function as
LECPs have been previously detected in malignant [28,37] and
wound healing models [13,38]. However, detailed molecular and
cellular characterization of these cells has been hindered by the
inability to isolate large numbers of phenotypically homogeneous
LECPs due to their low frequency in situ [27,28]. To overcome this
obstacle, we sought to establish a cell culture model that would
allow delineation of the molecular mechanisms driving macro-
phage differentiation into LECPs.
Towards this goal, we first characterized the endogenous LECPs
recruited to an inflammatory site. This was done in a mouse
peritonitis model induced by a single i.p. injection of LPS (50 mg), a
method reported to induce both macrophage recruitment [39] and
lymphangiogenesis in the diaphragm [17]. Resident control macro-
phages were obtained from the peritoneum of saline-injected mice.
LPS-activated and control CD11b
+cellswere isolatedusingmagnetic
beads conjugated to anti-CD11b antibody, and analyzed by flow
cytometry for dual expression of VEGFR-3 and CD11b. These cells
were also stained for the expression of the lymphatic markers LYVE-
1 and podoplanin as well as myeloid markers F4/80, CD11c and
Ly6C. Fig. 1A shows that resident macrophages can be split into two
populations (labeled as Ctrl-P1 and Ctrl-P2) whereas after LPS-
induced population can be subdivided into three subsets with distinct
scatter properties (designated as LPS-P1, LPS-P2 and LPS-P3). LPS-
P1 was likely comprised of mature macrophages as indicated by their
large size, 92% positivity for F4/80 [40] and low expression of other
markers (Fig. 1, Table 1). In contrast, the two smaller populations
were largely negative for F4/80 and highly positive (70–80%) for
Ly6C (Table 1). These two populations, LPS-P2 and LPS-P3, likely
represent monocyte progenitor cells recruited from the bone marrow
through blood vessels [41].
Although all three LPS-induced populations had increased
VEGFR-3 expression, the largest increase (3.37-fold) was associ-
ated with LPS-P2 as indicated by the shift from 7.7% in average in
control to 26.0% VEGFR-3
+ cells in LPS-treated mice (Fig. 1E,
Table 1). LPS-P2 cells also co-expressed LYVE-1 (8.1%),
podoplanin (33.5%), CD11c (36%) and Ly6C (80%) identifying
them as monocytic progenitors with pro-lymphatic phenotype.
LPS-P1 had similar 2.48-fold increase in VEGFR-3 whereas the
new LPS-P3 population contained 5.8% of VEGFR-3
+ cells.
These data indicate that several subsets of CD11b
+ macrophages
upregulate VEGFR-3 on their surface and might promote
inflammatory lymphangiogenesis as suggested by their co-
expression of lymphatic-specific markers.
CD11b
+/VEGFR-3
+ macrophages isolated from
LPS-treated mice display LECP phenotype
To characterize the phenotype of VEGFR-3
+ macrophages in
vivo, we isolated CD11b
+ macrophages from the peritoneal cavity
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populations that either expressed or lacked VEGFR-3. The sorted
populations designated as CD11b
+/VEGFR-3
+ and CD11b
+/
VEGFR-3
2 were then analyzed by RT-qPCR to compare the
expression of lymphatic- and endothelial-specific markers.
As expected, the level of VEGFR-3 mRNA was 35.662.5-fold
higher in CD11b
+/VEGFR-3
+ cells than in macrophages lacking
this receptor (Table 2). Importantly, this cell population was also
characterized by increased expression of many other LEC-specific
markers, including cMaf (2.5860.51-fold), CouptfII (5.2260.41-
fold), Itga9 (4.5060.16-fold), Lyve1 (41.263.3), Neuropilin2
(1.7360.28), Notch1 (1.8360.14), podoplanin (4.0560.18-fold),
Sox17 (4.0260.09-fold), Vegfr1 (4.0960.16), and Vegfc
(4.4160.42-fold). Notably, LYVE-1, a major lymphatic cell
marker, was robustly elevated by 41-fold in the CD11b
+/
VEGFR-3
+ subset compared with VEGFR-3
2 macrophages.
Prox1 was a single LEC phenotypic marker that was 2-fold
decreased in CD11b
+/VEGFR-3
+ cells compared with the
negative cells (Table 2). In comparison, several BEC-specific
markers were also decreased in this population including Cd34
(21.23-fold), Pecam1 (21.41-fold), Tie2 (21.48-fold) and Vegfr2
(22.39-fold). Collectively, these data show that VEGFR-3
+/
CD11b
+ macrophages display the tendency toward the lymphat-
ic-specific phenotype which is indicated by their relative
Figure 1. VEGFR-3 protein is elevated on several subsets of macrophage-derived LECP (M-LECP) in vivo. Balb/c mice were injected i.p.
once with 100 ul of sterile endotoxin-free saline or LPS (50 mg) and treated for 24 hours. (A) Cells were isolated using magnetic beads conjugated to
anti-CD11b antibody and analyzed by flow cytometry. Two major cell populations in control and three in LPS were identified and analyzed separately
for dual expression of CD11b and VEGFR-3. Gating is indicated by black lines. Populations P1 (B) and P2 (C) were found in both control and LPS-
activated CD11b
+ cells. (D) Population P3 was present only in LPS-treated mice. (B–D) Expression of VEGFR-3 on LPS-activated and control CD11b
+
isolated cells was analyzed. Numbers in each quadrant represent the percentage of positive cells for the indicated protein. Three independent
experiments were performed with similar results (for each experiment: n=5 mice per group). (E) Histogram of VEGFR-3 expression in population P2
showing the largest increase in VEGFR-3 protein expression in response to LPS treatment.
doi:10.1371/journal.pone.0031794.g001
Table 1. Expression of VEGFR-3 in subsets of CD11b
+ macrophages before and after treatment with LPS.
Ctrl-P1
{ LPS-P1 Ctrl-P2 LPS-P2 LPS-P3
Lymphatic Markers
VEGFR-3 3.760.6 9.260.8 (,0.001)
¥ 7.760.5 26.060.8 (,0.001) 5.860.5 (n.s.)
LYVE1 5.660.5 4.360.9 (,0.001) ND
1 8.160.8 (,0.05) 3.060.5
Podoplanin ND 9.160.2 (,0.01) 29.761.49 33.561.4 (0.001) 4.760.4 (,0.001)
Myeloid Markers
F4/80 84.461.2 92.361.9 (n.s.) ND ND 3.160.6 (,0.05)
CD11c ND ND 32.463.4 36.061.6 (,0.001) 3.760.7 (,0.001)
Ly6C ND 5.061.1 (n.s.) 5.960.4 80.363.4 (,0.05) 70.660.5 (,0.001)
{Percent of positively stained cells for indicated marker was determined by flow cytometry of isolated CD11b
+ cells collected from either untreated (control) mice or
those treated with 50 mg of LPS (n=20 for each group). Data are presented as the mean percent per group 6 SEM.
¥Statistical significance was determined by Student’s t-test comparing the differences between the same populations in control and LPS-treated CD11b-positive cells.
Both LPS-P2 and LPS-P3 were compared to Ctrl-P2 due to absence of the third population in the control samples. P-values are displayed in parentheses.
1ND, non-detected.
doi:10.1371/journal.pone.0031794.t001
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of BEC-associated proteins. This observation suggests that the
lymphatic-specific proteins expressed in this subset may aid in
recruitment of LECPs and their integration with lymphatic vessels
that subsequently undergo sprouting.
LPS-activated CD11b
+ macrophages are massively
recruited to the proximity of lymphatic vessels
To better understand the behavior of endogenous LECPs, we first
analyzed the kinetics of their recruitment into the diaphragm in
response to LPS. Group of 3 mice were daily treated with either
endotoxin-free saline or 20 mg LPS for three days. Diaphragms were
harvested at days 0 to 5 after the first injection and analyzed for co-
localization of macrophage markers, CD11b and F4/80, and
lymphatic marker, LYVE-1. All secondary IgG controls produced
minimal background (Fig. 2A, bottom row). Before LPS treatment,
diaphragms contained very few macrophages that were distantly
located in relation to the LYVE-1
+ vessels (Fig. 2A, Day 0). In sharp
contrast, 24 hours after LPS treatment, the numbers of tissue-
infiltrating macrophages were substantially increased by 3–4 folds in
a highly significant statistical manner with P-values of 0.04 and 0.006
for CD11b
+ and F4/80
+ cells, respectively (Figs. 2B and 2C). These
macrophages created large aggregates located in the close proximity to
the lymphatic vessels (Fig. 2A, Day 1 and Day 2). The peak of
macrophage recruitment was on Day 2 (Fig. 2). On Day 3, the
macrophage density was reduced by 20–30% compared with the peak
numbers; by Day 5 the density was undistinguishable from normal
level in untreated mice (Fig. 2). No change was recorded in LYVE-1
+
vessel density in the course of first week post-treatment (Fig. 2D)
indicating that interactions between pre-existing lymphatic vessels and
activated macrophages occur many days prior to genesis of new vessels.
LPS-activated endogenous macrophages integrate into
pre-existing lymphatic vessels in vivo
One of the most intriguing and unique properties of LECPs is
their ability to integrate into the existing vessels [28,31]. To
Table 2. Differences in gene expression in VEGFR-3
+ compared with VEGFR-3
2 macrophages.
Gene Fold change in gene expression
{ P-value
{ Gene Fold change in gene expression P-value
Increased Decreased
Bcl3 1.3760.17 ,0.01 Akt 21.2860.11 ,0.01
Bclxl 2.1360.09 ,0.05 Ang1 22.4760.46 ,0.01
Ccl5 4.6160.31 ,0.001 Ang2 21.7260.22 ,0.001
Ccr2 3.9560.16 ,0.001 Bcl2 29.4160.66 ,0.001
Ccr5 2.1560.03 ,0.001 Ccr1 21.2960.05 ,0.01
cMaf 2.5860.51 ,0.05 Ccr3 22.0860.26 ,0.001
CouptfII 5.2260.41 ,0.001 Ccr7 22.0860.10 ,0.001
Cox2 2.7160.14 ,0.001 Cd34 21.2360.02 n.s.
Cx3cr1 2.3660.13 ,0.001 cKit 23.4160.47 ,0.001
Foxc2 1.2760.15 n.s Cxcr4 21.7060.18 ,0.01
Il6 2.2760.17 ,0.05 Ets1 22.1760.25 ,0.001
Inos 1.5460.27 n.s Il1b 23.0660.57 ,0.01
Itga9 4.5060.16 ,0.01 Ltb 21.8060.14 ,0.05
Lyve1 41.2063.30 ,0.001 nfkb1 (p50) 21.4060.07 ,0.001
mTor 1.4760.01 ,0.01 Pecam1 21.4160.26 ,0.001
Neuropillin1 1.6760.27 n.s Prox1 22.3060.33 ,0.001
Neuropillin2 1.7360.28 n.s Rela (p65) 21.6760.04 ,0.001
Notch1 1.8360.14 ,0.05 Sox18 21.8260.20 ,0.001
Podoplanin 4.0560.18 ,0.001 Syk 21.9560.22 ,0.01
Slp76 1.3660.09 ,0.05 Tie2 21.4860.05 ,0.05
Sox17 4.0260.09 ,0.05 Tlr4 21.7460.18 ,0.001
Sox7 1.5660.15 n.s Tlr9 23.1960.90 ,0.01
Spred1 1.6960.37 n.s Tnfa 21.5260.22 ,0.001
Spred2 1.6160.12 n.s Vegfd 26.5160.51 ,0.01
Tlr2 2.8460.16 ,0.001 Vegfr2 22.3960.29 ,0.001
Vegfa 1.8160.20 ,0.05
Vegfc 4.4160.42 ,0.01
Vegfr1 4.0960.16 ,0.01
Vegfr3 35.6062.50 ,0.001
{Fold-change in gene expression was determined by RT-qPCR analysis of CD11b
+/VEGFR-3
+ and CD11b
+/VEGFR-3
2 macrophages from mice treated with 50 mgo fL P S
for 24 hours. Values are representative of pooled RNA from five independent experiments (total n=55 mice). Data were normalized per b-actin and presented as the
mean fold-change 6 SEM.
doi:10.1371/journal.pone.0031794.t002
Macrophage Differentiation to Lymphatic Phenotype
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e31794compare LECPs from this inflammatory model with those
described previously [28,31], we determined the extent and the
temporal pattern of incorporation of CD11b
+ and F4/80
+
macrophages into pre-existing lymphatic vasculature. Fig. 3 shows
representative serial sections from LPS-treated mice at day 0, 1 or
2 post-treatment that were double-stained with anti-LYVE-1 and
macrophage markers. We found that while recruitment to the
periendothelial lymphatic space and attachment to the LEC
surface occur mainly at the first day (Figs. 3A and 3B, Day 1), the
majority of integration events mainly occur at Day 2 post-
treatment in comparison with other days (Figs. 3C and 3D).
At the peak of integration phase, Day 2, nearly 50% of LYVE-
1
+ vessels co-expressed CD11b and F4/80 as indicated by the
yellow color on the merged images (Figs. 3A and 3B). The
differences in frequencies of co-localization between days 1–3 and
other days of the study were highly statistically significant with P-
values ranging between 0.045 and 0.002.
The integration phase identified by dual expression of the
lymphatic and myeloid markers began to slow down on the third
day of treatment reaching undetectable level on the fifth day
(Figs. 3C and 3D). This suggests that after the macrophages
incorporate into the lymphatic vessels, they lost the myeloid
markers while overexpressing the lymphatic markers making them
indistinguishable from the recipient cells. As shown on serial
sections in Figs. 3A and 3B, both the frequency and the extent of
integration of F4/80
+ macrophages were nearly identical to those
of CD11b
+ cells. This observation in consistent with the evidence
for VEGFR-3 upregulation in both resident and recruited LPS-
activated macrophages (Table 1), thus suggesting that both mature
and immature macrophages are sufficiently plastic to structurally
contribute to growing lymphatic vessels.
LPS-activated RAW264.7 macrophages in vitro display do
novo expression of VEGFR-3
Characterization of in vivo LPS-activated macrophages revealed
significant increase in VEGFR-3 expression in up to 26% of
CD11b
+ cells (Fig. 1, Table 1) concomitant with upregulation of
many other LEC-specific genes (Table 2). We hypothesized that
these events can be modeled in vitro using a macrophage cell line
RAW264.7 [42] activated by LPS. The rationale to create a new in
vitro, system modeling macrophage-LEC differentiation process
was the expected ability to perform in-depth molecular analyses
typically not achievable in vivo due to complexity at the whole
animal level.
Figure 2. LPS induces recruitment of CD11b
+ and F4/80
+ macrophages to the proximity of lymphatic vessels in vivo. (A) Balb/c mice
were injected with 20 mg of LPS for three consecutive days, and sacrificed daily to assess the kinetics of macrophage recruitment to the diaphragm.
Control mice represented by Day 0 received 100 ml of sterile, endotoxin-free saline. Diaphragms were co-stained for LYVE-1 and myeloid markers
CD11b (panel 1 labeled CD11b/LYVE-1) and F4/80 (panel 2 labeled F4/80/LYVE-1). Secondary controls for each single antibody staining and
combinations are presented in the bottom panel labeled ‘‘Sec. Alone’’. All images were acquired at 200X magnification. White arrows and arrowheads
point to LYVE-1 and myeloid markers, respectively. Note: integration as indicated by the yellow color mainly occurs on the second day. Sum of pixel
intensity per field was calculated as described in the Materials and Methods. (B) MFI of CD11b
+ positive staining 6 SEM per field. (C) MFI of F4/80
+
positive staining per field 6 SEM. (D) Average LYVE-1
+ structures per mm
2 of the diaphragm. Statistical significance (P,0.05) is denoted by asterisk.
doi:10.1371/journal.pone.0031794.g002
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e31794As a proof-of-principle for establishing such a system, we
characterized the sensitivity and the kinetics of inflammation-induced
VEGFR-3 expression in LPS-treated RAW264.7 macrophages in vitro.
To measure the sensitivity of VEGFR-3 induction, cells were activated
with 0–100 ng/ml of LPS for 24 hours followed by RT-qPCR
analysis. VEGFR-3 expression increased by 3.260.3-fold in response
to as little as 0.025 ng/ml of LPS followed by linear upregulation to
9.7-fold at 0.5 ng/ml of LPS, with no further increase above this dose
(Fig. 4A). To characterize the kinetics of VEGFR-3 expression, cells
were exposed to 100 ng/ml of LPS for 0–72 hours followed by RT-
qPCR analysis. Compared with control, VEGFR-3 expression
increased by 2.560.3-fold 4 hours post-exposure, peaked to 2062-
fold at 12 hours, and remained elevated by 2.360.3-fold at 72 hours
post-treatment (Fig. 4B). To determine whether mRNA correlated
with increased VEGFR-3 cell-surface protein, RAW264.7 macro-
phages were activated by 100 ng/ml of LPS for 24 hours and analyzed
by flow cytometry. Fig. 4C shows that LPS treatment increased cell-
surface VEGFR-3 protein by 32-fold (P,0.05) from 1.460.3% in
control macrophages to 45.064.1% in LPS-activated cell population.
Collectively, these data show that LPS atpicogram concentrations
induces significant changes in VEGFR-3 mRNA and protein
expression in both macrophage-derived LECPs in vivo and
RAW264.7 macrophages in vitro. These changes are characterized
by a rapid peak at 12 hours of a 20-fold increase in mRNA followed
by a 32-fold increase in surface-presented VEGFR-3 protein
24 hours post-exposure. The rapidity of this response, the precise
timing of mRNA upregulation, and the substantial increase in this
protein on cell surface all suggest an important regulatory role of
VEGFR-3 in early stages of macrophage differentiation into LECPs.
De novo expression of VEGFR-3 expression is preceded
by activation of NF-kB
We previously reported that p50 and p65 subunits of NF-kB
regulate VEGFR-3 expression on LECs in vitro and in lymphatic
vessels during inflammation in vivo [17,43]. We hypothesized that
LPS-induced VEGFR-3 in macrophage-derived LECPs might also
be regulated by NF-kB. To test this hypothesis, we compared the
expression of NF-kB p50, p65, and VEGFR-3 in RAW264.7
macrophages treated with 100 ng/ml of LPS or PBS for 0–
24 hours. Four hours after LPS treatment, transcripts of NF-kB
p50 and p65 increased respectively by 5.460.4 and 2.160.2-fold
(Fig. 5A). This was paralleled by an increase in total and
phosphorylated NF-kB p50 protein as well as phosphorylated
NF-kB p65 although non-phosphorylated p65 protein level
remained unchanged (Fig. 5B). Importantly, phosphorylation of
NF-kB proteins preceded VEGFR-3 upregulation by 4–8 hours
(Fig. 5B) suggesting that functionally-active NF-kB regulates
VEGFR-3 on the transcriptional level. We previously showed
that VEGFR-3 expression depends on activation of NF-kBb y
using an NF-kB inhibitor, leptomycin B [17]. Consistent with our
prior findings [17], treatment of RAW264.7 macrophages with
leptomycin B (10 nM) inhibited VEGFR-3 response to LPS in a
dose-dependent manner (Fig. 5C). Collectively, these data suggest
that NF-kB regulates transcription of VEGFR-3 in both LECs and
macrophage-derived LECPs.
LPS-treated RAW264.7 macrophages activate autocrine
VEGF-CNVEGFR-3 loop
Although NF-kB involvement suggested similarities between
macrophages and LEC with respect to regulation of VEGFR-3
expression, the major difference between these cell types is the
absence of detectable VEGFR-3 in resting macrophages or
undifferentiated myeloid progenitors prior to activation. Our data
Figure 3. LPS induces integration of endogenous M-LECP into LYVE-1
+ lymphatic vessels in vivo. Diaphragm tissues were co-stained with
anti-LYVE-1 and anti-CD11b or F4/80 antibodies. Panels A and B show representative images at days 0, 1, and 2 post-LPS treatment for all markers
stained singularly and combined with LYVE-1. All images were acquired using an objective of 60X (total 600X magnification). The forth column in
each panel (labeled Merged 2006) shows the merged image magnified 200-fold using Photoshop. On day 0 prior to LPS stimulation, CD11b
+ (A) and
F4/80
+ macrophages (B) were completely separated from LYVE-1
+ vessels. On day 1, subsets of CD11b and F4/80-positive macrophages were found
in close proximity to most LYVE-1
+ vessels. On day 2, CD11b and F4/80 markers were largely co-localized with LYVE-1 indicating integration of
endogenous macrophage-derived LECP into pre-existing LYVE-1
+ lymphatic vessels. White arrowheads indicate co-localization of the two markers. (C)
The mean percent of LYVE-1
+ vessels with CD11b
+ macrophages integrated into the vessels 6 SEM. The mean value is derived from analyzing al
lymphatic vessel in a diaphragm section for integration of M-LECPs from three individual mice per time point (total n=9–10). (D) Incorporation of F4/
80
+ macrophages was analyzed in a similar manner to that of CD11b
+ cells. The mean percent of LYVE-1
+ vessels with integrated F4/80
+ macrophages
6 SEM. Single asterisk and double asterisks indicate statistical significance of a P-value,0.01 and ,0.001, respectively.
doi:10.1371/journal.pone.0031794.g003
Figure 4. LPS upregulates VEGFR-3 mRNA and protein in
cultured RAW264.7 macrophages in a dose- and time-depen-
dent manner. (A) VEGFR-3 mRNA in RAW264.7 macrophages treated
with LPS (0–100 ng/ml) for 24 hours was analyzed by RT-qPCR and
compared with untreated controls (n=6 per group). (B) RT-qPCR
analysis of VEGFR-3 mRNA in RAW264.7 macrophages treated with
100 ng/ml LPS for 0 to 72 hours (n=9 per group). For (A) and (B),
relative transcript expression was normalized to b-actin. Data are
presented as b-actin normalized transcript expression 6 SEM. The P-
values represent **,0.01 and ***,0.001 versus control as determined
by Student’s unpaired t-test. (C) Flow cytometry analysis of VEGFR-3
protein expression on the surface of RAW264.7 macrophages that were
treated with 100 ng/ml of LPS for 24 hours. Values represent the
percentage of VEGFR-3
+ macrophages from 3 independent experiments
performed in triplicate 6 SEM (total n=9 per group).
doi:10.1371/journal.pone.0031794.g004
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VEGFR-3 expression: the response is transient, potent and fast.
This suggests that VEGFR-3 play a unique regulatory role in
transdifferentiation of macrophages into lymphatic progenitors.
We hypothesized that as a prerequisite for executing this role,
VEGFR-3 signaling must be induced in an autocrine manner.
This hypothesis was supported by the well-recognized ability of
inflammation-activated macrophages to overexpress VEGFR-3
ligands, VEGF-C and VEGF-D [39]. To test this hypothesis, we
first quantified expression levels of VEGF-C and VEGF-D in
RAW264.7 macrophages treated with 100 ng/ml of LPS for 0 to
24 hours. In contrast to some reports [44,45], LPS-activated
macrophages did not upregulated VEGF-D (Fig. 6A). In sharp
contrast, VEGF-C expression doubled after 2 hours of LPS
treatment followed by an exponentially increasing level up to
nearly 40-fold increase a day later (Fig. 6A).
Consistent with our hypothesis, this finding suggested that
simultaneous elevation of VEGFR-3 and VEGF-C may activate
autocrine signaling. To test for this possibility, LPS-treated
RAW264.7 macrophages (0–48 hours) were analyzed for tyrosine
phosphorylation on VEGFR-3 receptor by using immunoprecipi-
tation and Western blot to detect phosphotyrosine. As shown in
Fig. 6B, LPS linearly increased phosphorylation of VEGFR-3 up to
14-fold in a time-dependent manner, whereas soluble VEGFR-3-Fc
fusion protein completely blocked this event (Fig. 6C). Because
VEGFR-3-Fc specifically blocks VEGF-C-dependent activation
[46], these data present clear evidence for an inflammation-induced
VEGFR-3 autocrine loop, thus further underscoring the functional
significance of de novo expression of VEGFR-3 for macrophage
differentiation into lymphatic progenitors.
Autocrine VEGFR-3 signaling is followed by upregulation
of multitude of lymphatic genes mimicking the profile of
endogenous LECPs
The transient kinetic profile of VEGFR-3 expression (Fig. 4)
followed by induction of the autocrine loop (Fig. 6) suggested that
VEGFR-3 signaling at the early stages of macrophage transfor-
mation to LECPs might be essential for switching to the lymphatic
phenotype. To test this hypothesis, we analyzed the same set of
lymphatic-specific or -associated genes as was performed for
VEGFR-3-positive macrophage-derived LECPs in vivo (Table 2).
RAW264.7 cells were stimulated by 100 ng/ml of LPS for 5 or
24 hours followed by RT-qPCR analysis.
Compared with control macrophages, LPS-activated cells
significantly increased expression of several LEC markers
including VEGFR-3, VEGF-C, LYVE-1, Notch1, alpha integrin
9, c-Maf, and podoplanin. Moreover, phenotypic BEC markers
(e.g., CD34, Tie2, VEGFR-2 and neuropilin-1) were coincidently
downregulated (Table S1) suggesting a shift toward the lymphatic
phenotype. Furthermore, comparison of LPS-activated
RAW264.7 with CD11b
+/VEGFR-3
+ macrophages isolated from
an in vivo showed a 68% overlap in gene expression of 37 out of 54
examined genes. VEGFR-3, LYVE-1 and podoplanin were
among highly upregulated genes, as evidenced by 1260.2-fold,
17.160.45-fold, and 5,621689-fold increase in their mRNA
expression in LPS-treated RAW264.7 cells (Table S1). Important-
ly, as demonstrated in Figs. 6 and 7, the corresponding proteins for
these genes were absent in untreated macrophages and during
early stages of differentiation, but abundantly present after 10 to
12 hours. This de novo expression of exclusive lymphatic markers in
activated macrophages suggests that they play important roles in
defining the lymphatic identity in nascent progenitors and
preparing them for lymphatic vascular integration.
In vitro generated GFP-tagged RAW264.7-derived LECPs
integrate into lymphatic vessels in vivo
The ultimate test for generating experimental LECPs is their
demonstrable ability to incorporate into inflamed lymphatic vessels
in vivo. To determine the capacity of LPS-activated RAW264.7
cells to perform this essential LECP function, we first engineered a
sub-line that stably expresses GFP. As described in detail in the
Methods, several monoclonal GFP-labeled RAW264.7 line
Figure 5. Activation of NF-kB signaling precedes elevation of VEGFR-3 in LPS-treated RAW264.7 macrophages. (A) RT-qPCR analysis of
NF-kB p50 and p65 expression in RAW264.7 macrophages treated with 100 ng/ml LPS for 0–24 hours (n=6 per group). Relative transcript expression
was normalized to b-actin. Data presented as b-actin normalized transcript expression 6 SEM. The P-values represent *,0.05, **,0.01, and ***,0.001
versus control as determined by Student’s unpaired t test. (B) Protein expression of NF-kB p50 phosphorylated on Ser-337 (phospho-p50), non-
phosphorylated NF-kB p50, NF-kB p65 phosphorylated on Ser-276 (phospho-p65), non-phosphorylated NF-kB p65, VEGFR-3, and b-actin was
determined by Western blot in RAW264.7 macrophages treated with 100 ng/ml of LPS for 0–48 hours. Representative blot from two independent
experiments performed in triplicate wells is shown (total n=6 per time point). (C) RT-qPCR analysis of LPS-induced VEGFR-3 expression in the
presence of NF-kB inhibitor, leptomycin B. Relative transcript expression was normalized to b-actin. Data presented as b-actin normalized transcript
expression 6 SEM. CTRL (taken as 1) represents the mean basal VEGFR-3 expression in untreated RAW264.7 macrophages. The P-values represent
*,0.05, **,0.01, and ***,0.001 versus control as determined by Student’s unpaired t test.
doi:10.1371/journal.pone.0031794.g005
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proliferation and LPS response were combined to create a GFP-
tagged sub-line designated as RAW-GFP. This sub-line was
further taken for in vivo analyses designed to determine
biodistribution and vascular integration of RAW264.7 cell-derived
LECPs in saline-treated (control) and LPS-treated mice.
For the vascular integration assay, two groups of mice (n=5 per
group) were pre-treated with either sterile endotoxin-free saline or
20 mg LPS for three days. The mice were then injected with 2610
6
RAW-GFP cells, and sacrificed seven days after cell injection. The
presence and location of RAW-GFP cells in the collected
diaphragms was determined by staining with anti-GFP followed
by DyLight 549 conjugated secondary antibody that generated red
color. Because the fluorescent intensity of DyLight 549 is much
stronger than other conjugated dyes, we found that this method of
GFP-tagged cells is more reliable than staining with green
fluorescence emitting dyes or relying on the natural GFP
fluorescence. Using this method, we first determined on parallel
sections of diaphragms from LPS-treated mice that RAW-GFP
cells continued to strongly express not only GFP but also myeloid
(e.g., CD11b) and lymphatic (e.g., podoplanin) markers under in
vivo conditions (Fig. 8A). In contrast, F4/80, a late differentiation
myeloid marker [40], was only weakly detected in these cells
(Fig. 8A). At this time point (i.e., a week after injection) RAW-GFP
cells were negative for VEGFR-3, which is in line with the
transient nature of VEGFR-3 upregulation reported in this study
(Fig. 4).
Next, we determined whether RAW-GFP behave differently in
control and LPS-treated mice. Double immunostaining for LYVE-
1 and GFP identified very few recruited cells to the control
diaphragm (Fig. 8B, upper row), and a small percentage (4.8%) of
control lymphatic vessels to be associated with injected cells (Fig. 8,
B–D).In contrast, both density and the extent of vascular
incorporation of RAW-GFP in LPS-treated mice surpassed those
in the control mice by several folds. In contrast to the control
group, all mice in the LPS-treated group showed massive
recruitment of the RAW-GFP cells to the inflamed diaphragm,
with many humongous clusters strongly attached to the peritoneal
side of the diaphragm (Fig. 8B, bottom row). Moreover, LYVE-1-
positive vascular tube-like structures were frequently observed
within the RAW-GFP aggregates (white arrows in Fig. 8B, merged
and 200X). In addition to these macrophage-autonomously
generated lymphatic vessels outside of the tissue, RAW-GFP cells
also incorporated into the lymphatic vessels within the inflamed
diaphragm. The dual LYVE-1 and GFP staining identified
approximately 18% of the lymphatic vessels with coincident
expression of GFP (Fig. 8C). The extent of lymphatic vascular
integration was 3.75-fold higher in LPS-treated mice than in
control mice, the difference that was highly statistically significant
with a P-value of less than 0.001 (Fig. 8D). These data indicate that
LPS-activated RAW264.7 cells not only can model macrophage-
lymphatic transition in vitro but also reproduce the LECP behavior
in vivo.
Discussion
LECPs are defined as circulating BM-derived cells with de novo
expression of lymphatic markers and the capacity to integrate into
growing lymphatic vessels. Although LECPs have been observed
in human tissues [29,47,48] and animal models [28,30,31,35], the
progress in understanding their biology is currently impeded by
low frequency in vivo [27,28,30], inability to follow their fate due to
post-integration loss of myeloid markers, and most importantly,
lack of representative cell culture models. We sought to establish
an in vitro model reproducing the LECP phenotype that could be
Figure 6. LPS induces autocrine VEGFR-3 phosphorylation in RAW264.7 macrophages in vitro. (A) RT-qPCR analysis of VEGF-C and VEGF-
D mRNA expression in RAW264.7 macrophages treated with 100 ng/ml of LPS for 0–24 hours. The relative expression was normalized to b-actin. Data
are presented as the mean values performed in triplicate 6 SEM (total n=3). The P-values represent **,0.01 and ***,0.001 versus control as
determined by Student’s unpaired t test. (B) VEGFR-3 protein was immunoprecipitated using anti-VEGFR-3 antibodies from whole cell lysates of
RAW264.7 macrophages treated with 100 ng/ml of LPS for 0–48 hours. Immunoprecipitated proteins were blotted and probed with anti-pTyr and
anti-VEGFR-3 antibodies to determine phosphorylation status of VEGFR-3. Representative blot from two independent experiments performed in
triplicate is shown (total n=6 per timepoint). (C) RAW264.7 macrophages treated with 100 ng/ml of LPS for 24 hours in the presence of soluble
VEGFR-3-Fc or irrelevant antibody. VEGFR-3 protein was immunoprecipitated with anti-VEGFR-3 antibody and receptor phosphorylation was analyzed
by Western blot using anti-p-Tyrosine antibody. As a loading control, immunoprecipitated VEGFR-3 protein was re-blotted using anti-VEGFR-3
antibodies. Representative image is shown from one experiment performed in triplicate wells (n=3).
doi:10.1371/journal.pone.0031794.g006
Figure 7. LPS-treated RAW264.7 macrophages acquire lym-
phatic-specific gene expression. Western blot analysis of Prox1,
podoplanin, and LYVE-1 proteins in RAW264.7 macrophages treated
with 100 ng/ml of LPS for 0–48 hours. Representative blot from two
independent experiments performed in triplicate wells is shown (total
n=6 per timepoint).
doi:10.1371/journal.pone.0031794.g007
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cellular, and whole animal levels.
To this end, we used an immortalized macrophage cell line
RAW264.7 [42] that lacks LEC markers under normal conditions.
We found that LPS treatment of this line in vitro induces coincident
expression of VEGFR-3 and VEGF-C, which creates a positive
autocrine loop. This activation of VEGFR-3 signaling appears to
be a prerequisite for induction of a broad panel of lymphatic-
specific genes that are similarly upregulated in both endogenous
M-LECPs and LPS-stimulated RAW264.7 cells in vitro (Table 2
and Table S1). The LPS-activated RAW264.7 cells appear to
recapitulate several fundamental features of endogenous LECPs
including potent but transient expression of VEGFR-3, upregula-
tion of a diverse panel of lymphatic-specific markers, massive
infiltration into inflamed tissue, firm attachment to activated
lymphatic endothelium, and finally, widespread incorporation into
lymphatic vessels. These characteristics of LECPs found in the
peritonitis model (Figs. 1, 2, 3 and Tables 1–2) have been
previously identified in LECPs detected in a variety of other
inflammatory models [30,33]. Having access to a culture model
Figure 8. GFP tagged RAW264.7 cells (RAW-GFP) are recruited to LPS-treated diaphragms and undergo lymphatic vascular
integration in vivo. Balb/c mice were pre-treated with endotoxin-free saline or 20 mg of LPS for three consecutive days prior to i.p. injection of
2610
6 RAW-GFP cells. Seven days later, diaphragms were collected and analyzed for triple expression of GFP, lymphatic and myeloid markers. (A)
Characterization of RAW-GFP cells in vivo. Cells maintained the expression of GFP (panel 1), CD11b (panel 2), weak F4/80 (panel 3), and novel
expression of a lymphatic-specific marker, podoplanin (panel 4). All images were acquired at 400X magnification. (B) Recruitment of RAW-GFP to
inflamed, but not control, lymphatic vessels in the diaphragms of saline-treated mice or LPS. Upper panel: RAW-GFP cells were barely detected as a
few isolated cells in diaphragms of saline-treated mice. Bottom panel: Massive clusters of tightly adhered RAW-GFP were detected alongside of all
peripheral lymphatic vessels in the diaphragms of LPS-treated mice. Representative images from the groups of 3–4 mice are shown. All images were
acquired at 200X magnification. (C) RAW-GFP cells identified by anti-GFP specific antibody (red structures detected by DyLight 549-conjugated
secondary IgG) were found to be fully integrated into LYVE-1
+ vessels (green structures identified by FITC-conjugated secondary IgG to anti-LYVE-1).
Integration of RAW-GFP is clearly indicated by the yellow color on merged (acquired at 600X magnification) and 200-fold amplified merged images
(last column).
doi:10.1371/journal.pone.0031794.g008
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inflammatory lymphangiogenesis in vivo should allow us to dissect
the molecular details of this process.
LPS induces the lymphatic phenotype in endogenous
macrophages in vivo
Prior to establishing the cell culture model, we sought to
characterize the endogenous M-LECPs in a mouse peritonitis
model that has been previously used to demonstrate induction of
LPS- and macrophage-dependent inflammatory lymphangiogen-
esis [11,17]. We first focused on peritoneal macrophages that have
the potential to become LECPs. To our knowledge, such analysis
has not been done previously, although it can facilitate
understanding of the mechanisms regulating LECP recruitment,
infiltration into inflamed tissue, and subsequent integration into
vessels.
Using this model, we found that control mice had two distinct
populations of resident peritoneal macrophages whereas LPS-
treated mice had three. Importantly, all three LPS-induced
populations (LPS-P1, -P2 and -P3) had statistically significant
increases in VEGFR-3 expression (Fig. 1 and Table 1). The largest
increase was observed in LPS-P2, a subset that also expressed
LYVE-1, podoplanin, and a set of markers often found in BM-
recruited monocyte progenitors (i.e., CD11b
+/F480
2/CD11c
+/
Ly6C
high). The other two subsets (LPS-P1 and LPS-P3) contain 6–
9% of VEGFR-3
+ cells that might also be part of the LECP pool.
The LPS-P1 and -P3 subsets were characterized, respectively, by
the CD11b
+/F480
high/CD11c
2/Ly6C
2 and CD11b
+/F480
low/
CD11c
low/Ly6C
high profiles, and might represent an activated
resident and a recruited progenitor sub-population distinct from
LPS-P2. It, therefore, stands to reason that M-LECPs in the
peritonitis model might originate from at least three different
macrophage sub-populations: two major ones with high Ly6C
expression recruited from the bone marrow, and one minor subset
characterized by F480
high that might be derived from the resident
macrophages activated in situ.
VEGFR-3 might play a critical role in the early phase of M-
LECP differentiation
Although VEGFR-3 was highly expressed on up to 26–28% in
some populations of activated macrophages, this marker was
nearly undetectable on diaphragm-infiltrated macrophages after
the first day of treatment (Fig. S1). Analogously, LPS-treated
RAW264.7 cells in vitro showed a sharp bell-shaped pattern of
VEGFR-3 upregulation peaking at 12 hours and returning to the
basal levels after 48 hours (Fig. 4B). These similarities, in both the
potency and the transient nature of the expression, suggest that
VEGFR-3 plays a critical regulatory role at the early phase of
macrophage-to-LECP differentiation, but might not be required
for fulfilling later LECP functions. Studies on the RAW264.7 cells
also showed that co-expression of VEGFR-3 with VEGF-C
generate an autocrine loop (Fig. 6). It is, therefore, tempting to
propose that transient activation of VEGFR-3 autocrine signaling
may restrict the lymphatic path to selected subsets of progenitors
that undergo further pro-lymphatic differentiation by transcribing
lymphatic-specific genes that ultimately allow LECP integration
into lymphatic vasculature.
This concept is consistent with the substantial increase in a
variety of de novo transcribed lymphatic-specific or -associated
genes in both LPS-activated endogenous CD11b
+/VEGFR-3
+
macrophages (Table 2) and RAW264.7 macrophages in vitro
(Table S1). In addition to VEGFR-3, we also found high
upregulation of LYVE-1, podoplanin, COUP-TFII, Sox7, Notch1
and alpha 9 integrin. These genes upregulated in CD11b
+/
VEGFR-3
+ macrophages play critical roles in the formation of
embryonic lymphatic vasculature. For instance, the pro-lymphatic
roles of Sox7 and Notch1 have been shown to regulate VEGFR-3
in embryonic LECPs [49–51]. Likewise, genetic ablation of
endothelial COUP-TFII disrupts formation of the lymphatic
system due to inability of venous-derived LECPs to fully
differentiate into mature LECs [52,53]. LYVE-1 [54], podoplanin
[55], and integrin alpha9 [56] are all well-known specific markers
of LECs as well as their precursors [27,31]. These findings are,
therefore, consistent with the idea that LPS causes the lymphatic
differentiation in macrophages and monocyte progenitors by
forcing de novo expression of genes with critical roles in embryonic
lymphangiogenesis. This observation suggests that expression of
these genes in postnatal inflammation-activated macrophages
regulate LECP differentiation, and subsequently, support their
function in the newly-established lymphatic vessels.
Among all markers examined, two lymphatic endothelial
specific proteins, Prox1 and Tie2, were downregulated in
VEGFR-3
+ macrophages in both in vivo and in vitro assays. Prox1
has been detected in embryonic [32] and MSC-derived [35]
LECPs but not in adult LECPs originated from the myeloid
lineage. Taken collectively with our data, it might imply that
generation of M-LECP does not require Prox1 expression. Tie2
has been reported to be expressed in a subset of myeloid pro-
angiogenic progenitors [57,58], and, therefore, was a good
candidate for a marker of macrophage-derived precursors with
lymphangiogenic properties. However, both Tie2 mRNA (Table 2
and Table S1) and surface-expressed protein (not shown) were
found to be either downregulated or undetected in VEGFR-3
+
macrophages compared with controls. Tie2 expressing monocytes
(TEMs) have been reported to express F480
+/CD11c
2/Ly-6C
2/
LYVE-1
+ and implicated in promotion of tumor angiogenesis
[59]. In contrast, the subpopulation of M-LECPs we identified
were F480
2/CD11c
+/Ly-6C
+/LYVE-1
+ indicating a separate
subset of monocytes progenitors that are actively involved in
inflammatory lymphangiogensis (Fig. 3). Future studies in the LPS-
driven RAW264.7 model may clarify questions regarding potential
roles of Prox1 and Tie2 in inflammation-induced M-LECPs.
RAW264.7 macrophages treated by LPS in vitro acquire
the lymphatic phenotype
Analysis of LPS-activated cultured RAW264.7 macrophages
revealed significant upregulation of a broad panel of lymphatic-
specific genes consistent with de novo acquisition of the lymphatic
phenotype (Table S1). Increased at both mRNA and protein levels
(Table S1, Figs. 4, 5 & 7), these markers encompassed many
known pro-lymphangiogenic genes including VEGFR-3, podo-
planin, integrin alpha9, Notch1, and LYVE-1. Sixty-eight percent
of these genes were similarly detected in endogenous CD11b
+/
VEGFR-3
+ macrophages (Table 2) and in inflammation-induced
LECPs identified in independent studies [29,31,33,60]. These data
suggest that LPS-activated RAW264.7 macrophages in vitro
acquire the essential features phenotypic of LECPs detected at
lymphangiogenic sites in vivo.
One of the earliest upregulated genes in both RAW264.7 cells
and endogenous M-LECPs was VEGFR-3. Both endogenous and
RAW264.7 LPS-treated macrophages shared similarities in the
pattern of the VEGFR-3 response to the LPS characterized by
high sensitivity, rapidity and transient nature (Fig. 4). The
sensitivity of VEGFR-3 induction suggests a specific response
mediated by an LPS receptor, TLR4, rather than general response
to stress. This is also suggested by dependence of VEGFR-3
induction on NF-kB in both activated M-LECPs (Fig. 5) and
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However, in contrast to adult LECs, VEGFR-3 expression in
macrophages and macrophage-derived progenitors returned to the
basal levels within 48 hours (Fig. 4B). This suggests that VEGFR-3
is only necessary to set up the initial stage for differentiation but is
not required for maintaining the lymphatic identity.
Treatment with LPS upregulated both VEGFR-3 and VEGF-C
expressions thus creating a novel autocrine loop (Fig. 6). The
expression of VEGF-C by activated macrophages was previously
proposed to be important for chemotaxis of VEGFR-3
+
macrophages [37], integration of BM-derived VEGFR-3
+ LECPs
into lymphatic vessels [30], and induction of VEGFR-3 signaling
in differentiated LEC [8,44,45]. Our data suggest that in addition
to these functions, VEGF-C is also needed for activation of the
autocrine VEGFR-3 signaling that leads to transcription of LECP
differentiation genes. This hypothesis is consistent with studies
showing that VEGF-C treatment induces lymphatic differentiation
in progenitor cells such as ESC [61] and BMDC [31]. Moreover,
differentiation of ESC-derived LECPs has been shown to be
blocked by forced expression of either mutated [34] or a soluble
VEGFR-3 receptor [61]. These studies and our findings
collectively suggest that early activation of VEGFR-3NVEGF-C
axis in macrophages during inflammation might be necessary for
ensuring the lymphatic identity in progenitor cells as well as their
incorporation into lymphatic vessels.
The ultimate test for the ability of RAW264.7 cells to function
as LECPs is demonstration of their recruitment and integration
lymphatic vessels in vivo. We show here that GFP-tagged
RAW264.7 cells (RAW-GFP) indeed have the capacity to mimic
the behavior of endogenous M-LECPs in both recruitment to and
incorporation into inflamed lymphatic vessels. Like the endoge-
nous M-LECP that intimately associated with the lymphatic
endothelium prior to integration (Fig. 3), large aggregates of
RAW-GFP were detected in the proximity of the lymphatic vessels
in LPS-treated mice (Fig. 8). Moreover, 18% of the lymphatic
vessels co-expressed GFP and LYVE-1 indicating a significant
ability of experimentally generated M-LECPs to functionally
perform as native lymphatic precursors by structurally contribut-
ing to growing lymphatic vasculature.
Collectively, these data show that LPS-activated RAW264.7
cells not only phenocopy the lymphatic gene profile of endogenous
M-LECPs but also their functional capacity to integrate into
lymphatic vasculature.
The RAW264.7 model of macrophage-LECP
differentiation offers numerous advantages for studying
lymphatic biology in vivo
Our primary goal was to establish a cell-based model that would
allow in-depth characterization of macrophage differentiation into
LECPs observed during inflammatory lymphangiogenesis in vivo.
To this end, we selected a macrophage line RAW264.7 that
faithfully recapitulates the macrophage phenotype [62,63] and is
exquisitely sensitive to inflammatory stimuli. As such, it provides a
solid platform for studying macrophage transition to LECPs
induced by an inflammatory trigger such as LPS.
We showed that LPS-activated RAW264.7 macrophages
display the lymphatic-specific gene signature largely overlaps with
that of endogenous CD11b
+/VEGFR-3
+ LECPs (Table S1).
Many of the genes upregulated in LECPs in response to
inflammation (e.g., podoplanin, integrin alpha9, Notch1,
COUP-TFII, and Sox7) have been implicated in embryonic
lymphatic development, yet a similar function in adult has not
been established. The RAW264.7 macrophage model can be used
for defining the LECP-specific functions of these genes through
techniques, such as fluorescent labeling, gene knockdown, and
transgene overexpression. This line can easily be manipulated in
vitro to change the expression of these genes following by in vivo
transplantation into genetically compatible Balb/c mice [42]. We,
therefore, propose that this system designated for simplicity as ‘‘the
RAW model’’ can be used for in-depth analysis of the molecular
mechanisms regulating LECP functions in postnatal lymphangio-
genesis, a currently understudied field due to low frequency of
endogenous LECPs and the complexity of dissecting multifaceted
processes in vivo. We anticipate that the RAW model described
here will help to overcome current challenges in the field thus
opening the door for exciting new analyses of M-LECPs leading to
a better understanding of the lymphatic biology.
Materials and Methods
Ethics Statement
The animal experiments were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health. The
protocol was approved by the Laboratory Animal Care and Use
Committee of the Southern Illinois University School of Medicine
(protocol number 187-11-007).
Materials
LPS derived from Escherichia coli 055:B5, TRI-Reagent,
endotoxin-free sterile saline, protease inhibitor cocktail, and
PMSF were purchased from Sigma-Aldrich (St. Louis, MO).
Dulbecco’s modified Eagle’s medium (DMEM), Dulbecco phos-
phate buffered saline (DPBS), and all standard medium supple-
ments were from Lonza (Basel, Switzerland). Mouse anesthetic
cocktail consisted of ketamine (Fort Dodge Animal Health, Fort
Dodge, Iowa), xylazine (Phoenix Scientific Inc., St. Joseph, MO)
and sterile water.
Antibodies
We used the following primary antibodies: rat anti-mLYVE-1,
goat anti-mVEGFR-3, -mLYVE-1, and -GFP (R&D Systems,
Minneapolis, MN); hamster anti-mPodoplanin, rabbit anti-
mLYVE-1 and anti-Prox1 (AngioBio, Del Mar, CA); mouse
anti-phospho-tyrosine (p-Tyr), rabbit anti-p65, anti-p50, and anti-
phospo-p50 (Santa Cruz, Santa Cruz, CA); rabbit anti-phospo-
p65 (Epitomics, Burlingame, CA); mouse anti-b-actin, clone
JLA20 (Developmental Studies Hybridoma Bank, Iowa City,
IA); rat anti-F4/80 (Invitrogen, Carlsbad, CA); PE-conjugated rat
anti-mCD11b and anti-Ly6C; FITC-conjugated rat anti-CD11c,
and rat anti-Ly6G/C (Becton-Dickinson, Franklin Lakes, NJ); and
biotinylated rat anti-mTie2 (eBioscience, San Diego, CA).
Secondary antibodies conjugated to HRP, FITC, DyLight 488,
DyLight 549, and APC conjugated to donkey anti-rabbit and anti-
goat IgG, streptavidin and non-specific rabbit antibodies were all
from Jackson ImmunoResearch Laboratories (West Grove, PA).
Mouse model of LPS-induced peritonitis
Balb/c female mice (4–6 weeks) were obtained from Harlan
Laboratory (Indianapolis, IN) and treated in accordance with
institutional guidelines. Control mice were injected with 200 ml
sterile endotoxin-free saline. Peritonitis was induced by repetitive
i.p. injections on days 0, 1, and 2 with 20 mg of LPS dissolved in
200 ml of sterile endotoxin-free saline. On days 0, 1, 2, 3, 4 and 5
of the study, mice were anesthetized by a ketamine/xylazine
cocktail and perfused with 5 mM CaCl2 solution. Diaphragms
were collected from perfused mice and snap-frozen immediately.
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of LPS-recruited CD11b
+/VEGFR-3
2 and CD11b
+/VEGFR-
3
+ macrophages
Four independent experiments were performed using Balb/c
female mice injected i.p. with 50 mg of LPS diluted in 100 mlo f
sterile endotoxin-free saline (total n=50). Activated peritoneal
macrophages were collected 24 hours post-injection by lavage using
10 ml of cold DMEM with 10% FBS and double-stained with goat
anti-mVEGFR-3 and rat anti-mCD11b antibodies using the
followingprotocol. Cellswerecentrifuged at 100RCFfor5 minutes
and resuspended at a density of 1610
6 cells per 100 ml of F-buffer
(PBS containing 2.5% horse serum) supplemented with 4 mg/ml of
non-specific mouse IgG (Sigma, St. Louis, MO). After 15-minute
incubation on ice to block non-specific binding to Fc receptors, cells
were washed several times and resuspended in 100 ml of F-buffer
containing 4 mg/ml of goat anti-mVEGFR-3 antibody. After a 30-
minute incubation on ice, cells were washed three times in FACS
buffer and resuspended in 100 ml of the F-buffer containing 5 mg/
ml of APC-conjugated donkey anti-goat antibody and 2 mg/ml of
PE-conjugated rat anti-mCD11b antibodies. After additional 30-
minute incubation on ice, cells were washed again in F-buffer.
Following immunostaining, CD11b
+/VEGFR-3
2 and CD11b
+/
VEGFR-3
+ cell populations wereisolatedusing a FACSAriaII high-
speed cell sorter (Becton-Dickinson, Franklin Lakes, NJ). Based on
FACS analysis, the purity of CD11b
+ cells was greater than 95%.
After sorting, RNA was extracted from CD11b
+/VEGFR-3
2 and
CD11b
+/VEGFR-3
+ cell populations by TRI-Reagent, according
to the manufacturer’s protocol, and gene expression was analyzed
by RT-qPCR as described below.
Preparation of LPS-recruited peritoneal macrophages for
flow cytometry analysis
Mice were treated and peritoneal macrophages were harvested
by lavage (n=5–6 mice per group per experiment) as stated above.
CD11b
+ cells were isolated using rat anti-mCD11b magnetic
beads (Miltenyi Biotec, Auburn, CA) and fixed with 1%
paraformaldehyde for 15 minutes on ice. Fixed cells were
double-stained with goat anti-mVEGFR-3 and rat anti-mCD11b,
-mLYVE-1, -Ly6C, -F4/80, -CD11c, -mTie2, or hamster anti-
mPodoplanin antibodies as described above. Marker expression
was analyzed by flow cytometry using Accuri C6 flow cytometer
(BD Accuri Cytometers, Ann Arbor, MI). Similar procedure was
used to analyze expression of VEGFR-3 on cultured RAW264.7
macrophages treated with 100 ng/ml LPS or DPBS (control) for
24 hours. All analyses were reproduced in at least three
independent experiments.
Immunofluorescent staining
All antibodies were diluted 1:100 in PBST (pH 7.4, 0.1%
Tween-20) containing 5 mg/ml of BSA. Frozen sections were fixed
with acetone for 10 minutes, rehydrated in PBST for 10 minutes
and incubated for 1 hour at 37uC with primary antibodies against
macrophage markers (CD11b or F4/80) and mouse LYVE-1.
Slides were washed and incubated for 1 hour at 37uC with
DyLight 488- or 549-conjugated secondary antibodies. For double
immunofluorescent staining, sections were incubated with primary
and secondary antibodies at 37uC for 1 hour, respectively, with a
10 minute wash in PBST between steps. Slides were mounted in
Vectashield medium containing 4,69-diamidino-2-phenylindole
(DAPI) nuclear stain (Vector Labs, Orton Southgate, U.K.).
Images were acquired using an Olympus BX41 upright micro-
scope equipped with a DP70 digital camera and DP Controller
software (Olympus, Center Valley, PA).
Measurement of mean fluorescent intensity
The mean fluorescent intensity (MFI) of CD11b and F4/80
positive staining was calculated as described previously [17], with
slight modifications. Briefly, fluorescent images were acquired at a
constant exposure time at 200X magnification on an Olympus
BX41 upright microscope equipped with a DP70 digital camera
and DP Controller. To exclude background staining, sections
stained with secondary antibodies only were used to set the
exposure time to the level below background fluorescence. Digital
RGB images acquired at a constant exposure time were converted
to 8-bit grayscale. The fluorescent intensity for each pixel was
calculated using the histogram function of Image J (http://rsbweb.
nih.gov/ij/) that was set up in the linear intensity range of 0 to 255
arbitrary units. Using this scale, background fluorescent intensity
of tissues stained with secondary antibodies alone was less than
10 units. MFI was calculated as the mean of the total pixels above
background in four images per slide derived from individual mice
in each group (n=3 per group). The results are presented as
averaged MFI arbitrary units per group 6 SEM.
Quantification of LYVE-1
+ vessel density
Frozen sections of diaphragms were acetone-fixed for 10 min-
utes and stained with antibody against the lymphatic-specific
marker, LYVE-1, for 1 hour at 37uC, followed by incubation with
DyLight 488-conjugated donkey anti-rabbit secondary antibodies
for 1 hour at 37uC. To quantify LYVE-1 positive vessel density, all
LYVE-1
+ structures in the diaphragm section were enumerated.
The total area of the diaphragm was then measured using Image J
software. LYVE-1 counts were then normalized per mm
2 of
diaphragm area. Lymphatic vessel density is presented as the
normalized number of LYVE-1
+ vessels per area of the field 6
SEM (n=3–4 mice per group).
Quantification of M-LECP incorporation into LYVE-1
+
vessels
Diaphragms were double-stained for CD11b or F4/80 and
LYVE-1 antibodies. Each LYVE-1
+ vessel in the diaphragm
section was individually assessed for co-localization with anti-
CD11b and anti-F4/80 antibodies using different filters in
Olympus BX41 microscope. The percentage of incorporated
vessels was calculated by dividing the number of LYVE-1
+vessel
with incorporated macrophages by total number of LYVE-1
+
vessels in the diaphragm section. The results are presented as the
mean percent of vessels with incorporated M-LECP 6 SEM
derived from 3 mice per group.
RT-qPCR analysis
Two micrograms of total RNA was reverse transcribed using a
RevertAid First Strand cDNA synthesis kit, according to the
manufacturer’s protocol (Fermentas, Burlington, Ontario, Cana-
da). Primers for RT-qPCR were designed against mouse and
human CDS of angiogenic and lymphangiogenic proteins found in
the NCBI database. Primer sequences were chosen using the
Harvard primer database website (http://pga.mgh.harvard.edu/
primerbank/index.html) and validated for specificity and primer
efficiency. All primers (listed in supplementary Table S2) were
purchased as annealed oligos from Integrated DNA Technologies
(Coralville, IA). Quantitative RT-PCR was performed using
GoTaq qPCR Master Mix (Promega, Madison, WI) and either
an ABI 7500 Real-Time (Applied BioSystems, Foster City, CA) or
a Mastercycler ep realplex (Eppendorf, Hamburg, Germany) PCR
machine. A typical reaction consisted of an initial denaturation
step at 95uC for 5 minutes followed by 40 cycles of denaturation at
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acquisition at 60uC for 1 minute. A final melting curve for each
primer was calculated by heating from 60uCt o9 0 uC. Data were
normalized to b-actin and relative mRNA expression was
determined using the DDCt method described previously [35,64].
Immunoprecipitation and Western blot analysis
The mouse RAW264.7 macrophage cell line (ATCC, Manas-
sas, VA), was cultured in DMEM supplemented with 10% FBS
and standard additives. For analysis of VEGFR-3 phosphoryla-
tion, RAW264.7 macrophages were treated with 100 ng/ml of
LPS for 0–48 hours. In some experiments, RAW264.7 macro-
phages were pre-treated for 2 hours with soluble VEGFR-3-Fc
recombinant protein (3 mg/ml; R&D Systems, Minneapolis, MN),
followed by stimulation with 1 ng/ml of LPS for 24 hours.
Following treatment, cells were washed twice with ice-cold DPBS,
lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton-X100, 0.1% SDS, 200 mM
PMSF, protease inhibitors and phosphatase inhibitor cocktails),
and spun down for 10 minutes at 13,000 RCF to remove insoluble
material. Protein concentration was determined by Bradford
assay, and 750 mg of lysate protein was incubated with 2 mg of goat
anti-mVEGFR-3 antibodies (R&D Systems, Minneapolis, MN) for
12 hours at 4uC. VEGFR-3 protein-antibody complexes were
precipitated by incubating with 30 ml of magnetic beads
conjugated to protein G (4 hours at 4uC). Beads were washed
thrice in ice-cold lysis buffer and VEGFR-3-antibody complexes
were eluted by boiling for 10 minutes in 50 ml of Laemmli buffer
containing 10 mM DTT. Eluted proteins were separated in a 9%
SDS-PAGE gel, transferred to nitrocellulose membranes that were
blocked with 5% milk in PBST for 1 hour, and incubated
overnight at 4uC with anti-pTyr antibody. Membranes were
washed thrice with PBST, followed by 1 hour incubation at room-
temperature with HRP-conjugated secondary antibodies. After
additional washing in PBST, membranes were developed with
ECL (Pierce, Rockford, IL) for 5 minutes. Protein bands were
visualized using a Fujifilm LAS-3000 camera and analyzed with
Image-Reader LAS-3000 software (Valhalla, NY). To visualize the
total amount of VEGFR-3 pull-down, membranes were stripped
with buffer consisting of 1.5% glycine (w/v), 0.1% SDS, 1%
Tween-20, pH 2.2, following by re-probing with anti-VEGFR-3
and HRP-conjugated secondary antibodies.
To analyze the kinetics of NF-kB and LEC-specific protein
expression, RAW264.7 macrophages were treated with 100 ng/ml
of LPS for 0–48 hours and analyzed by Western blot as described
above. Protein lysates were separated on 9–12% SDS-PAGE gels
and probed overnight at 4uC with antibodies against Prox1,
VEGFR-3, podoplanin and LYVE-1, followed by 1 hour
incubation with species-appropriate HRP-conjugated secondary
antibodies. Protein bands were detected as described above and
densitometric analysis was performed using Image J software.
Generation of RAW264.7 cells tagged with Green
Fluorescent Protein (GFP)
RAW264.7 cells were seeded at a density of 200,000 cells per
well in a 6-well plate with 2 ml of DMEM. Cells were allowed to
adhere to the plate overnight. Cells were washed with serum-free
DMEM for 20 minutes before adding supernatant containing a
GFP-encoding lentivirus with SFFV promoter (a generous gift
from Dr. Wilber, SIU School of Medicine). Medium was refreshed
24 hours later and GFP-expressing cells detected by direct
microscopy in the subsequent week were isolated using FACS.
The enriched population was then sub-cloned by a limiting
dilution in a 96-well plate. Cells derived from monoclonal colonies
with homogeneous GFP expression and parental morphology were
selected for further analyzes. Clones were expanded and tested for
identical and unaltered proliferation rate as well as LPS response
as compared with the unmodified RAW264.7 cell line. Several of
these clones were combined to create a GFP-tagged RAW264.7
sub-line designated here as RAW-GFP.
RAW-GFP macrophage incorporation into pre-existing
LYVE-1
+ vessels
Balb/c female mice were injected with 200 ml of sterile
endotoxin-free saline (control group) or 20 mg of LPS for three
consecutive days. After stimulation, mice were injected with 2610
6
of untreated RAW-GFP cells i.p. After 7 days, mice were
sacrificed; the diaphragms were harvested and analyzed by
immunofluorescence for expression of GFP and co-localization
of GFP with myeloid and lymphatic markers.
Statistical analysis
Statistical analysis was performed using SAS software (SAS
Institute, Inc., Cary, NC). All results are expressed as the mean 6
SEM and statistical differences were assessed by unpaired
Student’s t-test. Statistical significance was defined as P,0.05.
Supporting Information
Figure S1 CD11b
+ macrophages are recruited to VEGFR-3
+
vessels. Balb/c mice were injected with 20 mg of LPS once, and
sacrificed daily thereafter to determine whether the recruited
macrophages express VEGFR-3. Diaphragms were co-stained for
VEGFR-3 and CD11b (upper panel). LYVE-1
+ vessels recruited
CD11b-posiitve macrophages but these macrophages were largely
negative for VEGFR-3. Secondary controls for each single antibody
staining and combinations are presented in the lower panel. All images
were acquired at 200X magnification.
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Table S1 Relative change in gene expression profile of
LPS-activated vs. untreated RAW264.7 macrophages.
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